No Data
Jefferies Adjusts WuXi Biologics (Cayman)'s Price Target to HK$45 From HK$35, Keeps at Buy
Wuxi Biologics ADR Reports FY Results
Daiwa Capital Markets: Raised WUXI BIO (02269) Target Price to HKD 35, rating "Buy".
The group stated that, due to a significant increase in new projects, the revenue scale of Phase III and commercialization projects continues to expand, therefore the target is to achieve a revenue growth of 12% to 15% this year, with an acceleration in growth starting next year.
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks
Trending Industry Today: WUXI XDC Leads Gains In Biotechnology Stocks
COWmustMoo : this one may be a VCP break up
COWmustMoo : nice daily chart.. hourly too
AaronW : How many shares of WuXi AppTec are held, has the value of the sellable financial Assets appreciated?